(Q34986821)

5 August 2017

1 reference

title

Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects (English)

1 reference

5 August 2017

0 references

Pender MP

1

1 reference

5 August 2017

Wolfe NP

series ordinal

2

1 reference

5 August 2017

publication date

1 November 2002

1 reference

Internal Medicine Journal

5 August 2017

published in

1 reference

5 August 2017

volume

32

1 reference

5 August 2017

issue

11

1 reference

5 August 2017

page(s)

554-563

1 reference

Axonal transection in the lesions of multiple sclerosis

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Axonal pathology in multiple sclerosis: relationship to neurologic disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Survival in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

The use of interferon beta at the time of initial diagnosis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Overview of azathioprine treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Autologous stem cell transplantation in progressive multiple sclerosis--an interim analysis of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

T cell vaccination in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Apoptosis of inflammatory cells in immune control of the nervous system: role of glia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Preventing multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

The occurrence of autoimmune diseases in patients with multiple sclerosis and their families

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Relapses and progression of disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Autoimmune events during interferon beta-1b treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

B cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis: roles of B cell CD95, CD95L and Bcl-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00269.X

10.1046/J.1445-5994.2002.00269.X

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference